Business context and reporting period
Issuer discrepancy: The filing is for Integrity Applications, Inc., not Glucotrack, Inc. It is a Form 10-K for the fiscal year ended December 31, 2015—not a standalone fourth-quarter filing. The company develops GlucoTrack, a non-invasive glucose monitor; its financial statements are in U.S. dollars.
GlucoTrack had CE Mark approval in the EU, including 2015 approvals for device improvements and use by people with pre-diabetes. It was not approved for U.S. commercial sale. The company reported very limited product revenue and remained dependent on external financing.
Financial performance and liquidity
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $143,167 | $59,775 |
| Operating expenses | $4,798,520 | $3,667,134 |
| Operating loss | $4,655,353 | $3,607,359 |
| Net income (loss) | $(5,842,172) | $2,980,426 |
| Net cash used in operations | $4,565,224 | $3,361,645 |
| Cash at year-end | $608,701 | $5,827,560 |
Revenue rose about 140% from a low base. The company did not report a clear gross margin; cost of revenue is not separately presented. The 2014 profit reflected a large non-cash gain from changes in the estimated fair value of warrants, so it is not a useful indicator of recurring operating profitability. In 2015, financing expense included a $1,284,354 non-cash loss from exchanging Series A securities for Series B securities.
At December 31, 2015, current assets were $1.71 million and current liabilities $1.51 million; these included $816,223 of inventory and $1,082,546 of accounts payable. Total liabilities were $2.17 million, with $160,314 of long-term stockholder loans and no reported bank borrowing balance. Preferred stock is presented as temporary equity, not debt. Stockholders’ deficit was $6.97 million and accumulated deficit $29.38 million.
Operating cash use increased year over year. Accounts payable rose by $982,215, partly reflecting deferred payments; inventory increased by $737,554. Investing activities used $203,167 and financing activities used $460,863 in 2015, including repayment of the Dimri loan and Series A cash dividends. The company raised no new preferred-unit capital in 2015.
Material changes, outlook and key risks
- Management postponed sales in the second half of 2015 while implementing product improvements. It reported first-quarter 2016 orders of approximately $300,000, with over $100,000 collected, and a further $1.75 million of orders contingent on local regulatory approvals; those contingent orders were unpaid and not assured.
- Management expected to begin U.S. clinical trials in the first half of 2016, conditional on FDA protocol approval and sufficient funding. China and Japan regulators requested additional trials, extending the expected review process by 18–24 months or longer. South Korean approval was also delayed by regulatory questions.
- Wistron had produced a pilot batch; production-line operation was expected in the second or third quarter of 2016, subject to a satisfactory GMP audit. Commercial supply depended on third-party manufacturers and distributors.
- The auditor expressed substantial doubt about the company’s ability to continue as a going concern. Cash was approximately $84,000 on March 28, 2016, and management said it expected less than 30 days of runway from the report date. The company had deferred accounts-payable and certain management payroll payments and needed near-term financing; failure to obtain it could force cutbacks or cessation of operations.
- Financing risks include potential dilution and preferred-stock protections, including anti-dilution and most-favored-nation provisions, dividend obligations, covenants, and possible redemption triggers. The company also faces regulatory, reimbursement, commercialization, manufacturing, competitive, and limited-trading-market risks.
- The Dimri arbitration was settled in 2015: company-related parties paid approximately $439,939 in loan principal and $81,870 toward legal fees, while individuals transferred 440,652 company shares. The parties released related claims.
Important facts for investors to verify
- Confirm the issuer identity: this filing names Integrity Applications, Inc., despite the request metadata naming Glucotrack, Inc.
- Verify subsequent financing, cash runway, deferred payables and payroll, and whether operations continued after the March 2016 disclosures.
- Check whether the reported first-quarter orders were delivered, collected, and recognized as revenue, and whether the $1.75 million contingent orders converted to firm sales.
- Track FDA trial authorization and funding, as well as local approvals and requested trials in South Korea, China, and Japan.
- Assess dilution and potential obligations from preferred stock, warrants, dividends, and redemption provisions; also verify manufacturing readiness and distributor purchase performance.